Xiaoyu Wen

Dr. Xiaoyu Wen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SQShukui Qin
Shukui Qin
FBFeng Bi
Feng Bi
SGShanzhi Gu
Shanzhi Gu
YBYuxian Bai
Yuxian Bai
ZCZhendong Chen
Zhendong Chen
FCFeng Chen
Feng Chen
PURPOSE: Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC.PATIENTS AND METHODS: This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score ≤ 7, and no prior systemic therapy from 37 sites across China. Patients were randomly assigned (1:1) to receive oral donafenib (0.2 g) or sorafenib (0.4 g) twice daily until intolerable toxicity or disease progression. The primary end point was overall survival (OS), tested for noninferiority and superiority. Efficacy was primarily assessed in the full analysis set (FAS), and safety was assessed in all treated patients.RESULTS: Between March 21, 2016, and April 16, 2018, 668 patients (intention-to-treat) were randomly assigned to donafenib and sorafenib treatment arms; the FAS included 328 and 331 patients, respectively. Median OS was significantly longer with donafenib than sorafenib treatment (FAS; 12.1 v 10.3 months; hazard ratio, 0.831; 95% CI, 0.699 to 0.988; P = .0245); donafenib also exhibited superior OS outcomes versus sorafenib in the intention-to-treat population. The median progression-free survival was 3.7 v 3.6 months ( P = .0570). The objective response rate was 4.6% v 2.7% ( P = .2448), and the disease control rate was 30.8% v 28.7% (FAS; P = .5532). Drug-related grade ≥ 3 adverse events occurred in significantly fewer patients receiving donafenib than sorafenib (125 [38%] v 165 [50%]; P = .0018).CONCLUSION: Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YSYueming Shao
Yueming Shao
XYXin Yin
Xin Yin
TQTingting Qin
Tingting Qin
RZRuihua Zhang
Ruihua Zhang
YZYu Zhang
Yu Zhang
XWXiaoyu Wen
Xiaoyu Wen
Background and Aims. There are few studies on the prevalence and clinical characteristics of portopulmonary hypertension (POPH) in patients with portal hypertension. In addition, invasive right heart catheterization further limits the clinical diagnosis of POPH patients. Methods. From January 2018 to December 2019, 1004 patients with portal hypertension were treated in the Department of Hepatology, the First Hospital of Jilin University. Based on the inclusion and exclusion criteria, 188 patients with portal hypertension were finally included. We collected complete clinical data, laboratory examinations, and imaging examinations. Patients were divided into a POPH group and a non‐POPH group based on echocardiographic results. We calculated the prevalence of POPH in patients with portal hypertension. The differences in clinical characteristics of the two groups of patients were compared. Results. The prevalence of POPH in patients with portal hypertension was 2.8%. Among the 188 patients with portal hypertension with fingertip oxygen saturation < 95% at rest, 28 patients had POPH (12 males and 16 females), with an average age of 63 ± 8, and 160 patients did not have POPH (110 males, 50 women), with an average age of 59 ± 11. The proportion of women in the POPH group (P < 0.01) and patients without liver cancer (P = 0.044) was high. Compared to patients without POPH, patients with POPH had lower hemoglobin (related to the severity of anemia, P < 0.01), higher creatinine (P < 0.05), and lower partial pressure of oxygen and carbon dioxide (P < 0.05). Patients with POPH had a higher incidence of atrial enlargement, ventricular enlargement, mitral valve regurgitation, tricuspid regurgitation, pulmonary artery widening, pericardial effusion, and aortic regurgitation than those without POPH. The risk of POPH did not increase with the aggravation of the Child‐Pugh classification. Conclusion. The prevalence of POPH in patients with portal hypertension is 2.8%. The proportion of women and nonliver cancer in POPH patients was higher than that in non‐POPH patients. In addition, the POPH group had higher creatinine and lower hemoglobin, and echocardiography showed that POPH patients had more cardiac structural changes. In patients with portal hypertension, the risk in patients with POPH has nothing to do with the Child‐Pugh classification and MELD score.

9 December 2024 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Open access
YTYu Tian
Yu Tian
DHDiandian Hao
Diandian Hao
JDJialin Du
Jialin Du
HWHui Wang
Hui Wang
XWXiaoyu Wen
Xiaoyu Wen
Objective: This study aimed to summarize the clinical and microbiological characteristics of patients with pyogenic liver abscess (PLA) and to explore the clinical features of PLA with extrahepatic migratory infection (EMI). Methods: A retrospective analysis was conducted on clinical data from 1800 PLA patients at Jilin University First Hospital from January 2019 to December 2023. Patients were divided into two groups based on the presence of EMI: with EMI and without EMI. Clinical features and prognoses of the two groups were compared using rank-sum tests and chi-square tests for continuous and categorical data, respectively. Results: PLA patients were predominantly male (65.56%) with an average age of 60. Abscesses were mainly located in the right lobe (64.83%) and were often single (68.17%). Klebsiella pneumoniae was the primary pathogen (68.46%), with 9.50% of strains being multidrug-resistant. The majority of patients improved with effective treatment (96.17%). Compared with the non-EMI group, patients with EMI were younger, had longer hospital stays, smaller abscesses, and a higher incidence of diabetes and cerebrovascular disease, with poorer prognoses. Conclusion: PLA is most commonly observed in middle-aged and elderly males, often presenting as single abscesses in the right lobe, with diabetes as a frequent underlying condition. Most patients recover with appropriate antibiotic treatment and ultrasound-guided drainage. PLA patients with EMI generally have poorer outcomes and require special attention.

28 November 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
DHDian-Dian Hao
Dian-Dian Hao
GSGuang-Zhao Shao
Guang-Zhao Shao
XWXiu-Li Wang
Xiu-Li Wang
CZChang-Cheng Zhao
Chang-Cheng Zhao
JDJia-Lin Du
Jia-Lin Du
XWXiaoyu Wen
Xiaoyu Wen
Background: Patients with liver abscess are at high risk of developing invasive K. pneumonia liver abscess syndrome (IKPLAS), which can worsen survival and quality of life. Early identification of high-risk patients is crucial. This study aimed to identify risk factors for IKPLAS and develop a predictive model to guide early intervention. Methods: We retrospectively collected data from 1,762 liver abscess patients at the First Hospital of Jilin University between 2015 and 2024. Patients were randomly divided into a training set and an internal validation set at a 7:3 ratio, and 203 patients from another hospital served as an external validation cohort. The SMOTE algorithm was applied to address data imbalance. Independent risk factors were identified using LASSO and logistic regression analyses, and the performance of different models was compared. Ultimately, a LASSO-based logistic regression model was used to construct a predictive nomogram. Model performance was comprehensively evaluated using the area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), clinical impact curve (CIC), and calibration curve. An online risk calculator was also developed for clinical use. Results: Among 1,965 patients (1,304 males, 661 females; mean age 58.96 ± 13.07 years), 548 (28.9%) developed IKPLAS. Independent risk factors included CRP (OR = 1.005, 95% CI: 1.003–1.007), PLT (OR = 0.995, 95% CI: 0.994–0.997), Prior biliary disease (OR = 1.137, 95% CI: 1.025–2.571), Fever (OR = 2.196, 95% CI: 1.292–3.824), Pleural effusion (OR = 7.355, 95% CI: 4.883–14.761), Ascites (OR = 8.786, 95% CI: 5.141–9.342), Broth culture (OR = 2.264, 95% CI: 1.186–3.371), DM (OR = 2.516, 95% CI: 1.757–3.63), and TBIL (OR = 1.006, 95% CI: 1.002–1.010). The nomogram achieved AUCs of 0.960, 0.920, and 0.892 in the training, internal, and external validation sets, respectively, with good calibration and clinical utility. Conclusion: We developed a nine-factor nomogram to predict individualized IKPLAS risk, demonstrating high discrimination and calibration, supporting early identification of high-risk patients and personalized management.

8 December 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYu Zhang
Yu Zhang
HGHui Gao
Hui Gao
YSYue-Ming Shao
Yue-Ming Shao
RZRui-Hua Zhang
Rui-Hua Zhang
XWXiaoyu Wen
Xiaoyu Wen
Objectives: Changes in serum levels of cytokines have been proposed as possible biological markers of tissue damage, including drug-induced liver injury (DILI). Here, we aimed to screen cytokine markers that have guiding significance for the degree of inflammation of DILI.Patients and methods: 54 patients with DILI were retrospectively analyzed as the experimental group, and 14 healthy subjects were randomly selected as the control group. A total of 20 cytokines were detected by using a cytokine protein antibody chip, and differentially expressed proteins were screened.Results: There were significant differences in serum cytokines between DILI patients and healthy controls. Compared with the control group, the DILI group expressed 11 differential proteins. IL-8, TNF RII, TNFα, TNF RI, MIP-1β, MIP-1α, and IL-1β were differentially expressed in DILI patients with different degrees of inflammation from G1 to G4. MIG, IL-12p40, and IL-10 were differentially expressed in the higher degree of inflammation groups (G2, G3, and G4 groups). Tissue inhibitor of metalloproteinases-1 (TIMP-1) was differentially expressed in the group with the highest inflammation degree (G4 group). Chemokine C-C motif ligand 1 (I-309) was only differentially expressed in the lowest inflammation group (G1 group).Conclusion: The changes and differential expression of specific cytokine levels were helpful for evaluating different degrees of inflammation of DILI.

29 January 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
YRYu-Lin Ren
Yu-Lin Ren
XSXiang-Rui Song
Xiang-Rui Song
XHXi-Jie He
Xi-Jie He
XWXiaoyu Wen
Xiaoyu Wen
Objectives: Drug-induced liver injury (DILI) is a recognized adverse drug event. Although most cases present with acute hepatic damage, evidence indicates that a proportion progress to persistent liver injury. The absence of a standardized definition for chronic DILI has contributed to significant discrepancies in reported incidence rates across clinical studies. This meta-analysis aims to determine the pooled incidence of chronic DILI, providing robust epidemiological evidence. Methods: This meta-analysis was conducted in accordance with the PRISMA and MOOSE guidelines. A systematic search was conducted in PubMed, Web of Science, Embase and Cochrane Library databases from their respective inception dates to 11 July 2025. The quality of cohort studies was assessed using the NOS. A random-effects model was used to calculate the pooled incidence of chronic DILI, expressed as corresponding 95% confidence intervals ( CI s). Subgroup analyses were performed to explore potential sources of heterogeneity. Publication bias was assessed and sensitivity analyses were conducted. All statistical tests were two-tailed, and a P value <0.05 was considered statistically significant. Results: A total of 24 studies were included in the final analysis. The pooled incidence of chronic DILI (based on a duration of liver injury lasting more than 6 months without distinguishing the suspected drugs) was 14.09% (95% CI : 10.35%–18.29%; I 2 = 80.76%). Four studies that reported the incidence of chronic DILI based on a 12-month follow-up (without distinguishing causative drugs) showed a pooled incidence of 7.95% (95% CI : 5.16%–11.24%; I 2 = 54.8%). The pooled incidence of chronic DILI attributed to antimicrobial drugs (6-month follow-up) was 14.56% (95% CI : 10.86%–18.65%; I 2 = 0%). Conclusion: Chronic DILI accounts for a clinically certain proportion of DILI cases. Greater emphasis should be placed on the long-term management and follow-up of patients with DILI to mitigate the risk of chronic progression. Systematic Review Registration: https://inplasy.com , identifier INPLASY202580021.